Home › Funds › Novo Holdings A/S › DYN

Novo Holdings A/S position in DYN

DYNE THERAPEUTICS INC · Health Care

Novo Holdings A/S reported holding 1,376,164 shares of DYN (DYNE THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$22.2M, representing 1.49% of its reported portfolio and ranking #20 among its reported holdings. Novo Holdings A/S has disclosed DYN holdings in 2 of the last 2 reported quarters, going back to Q2 2026.

Latest position (Q3 2026)1.38M sh
Reported value held$22.17M
Portfolio Weight1.49%
First reportedQ2 2026
Last changeAdd
Updated2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

How Novo Holdings A/S's DYN position evolved

Novo Holdings A/S first disclosed a stake in DYN in Q2 2026 at 960,394 shares (US$21.3M). The position peaked in Q3 2026 at 1,376,164 shares, worth US$22.2M. Across 2 filings, Novo Holdings A/S increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 1,376,164 shares valued at US$22.2M — an increase of 415,770 shares quarter over quarter.. Notable position changes include a 43% increase in Q3 2026 (shares rose 4% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q2 2026 960.39K $21.33M New
Q3 2026 1.38M $22.17M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About DYN and 13F data

DYN (DYNE THERAPEUTICS INC) is a Health Care company. 34 other funds we track also report a position in DYN — the largest reported positions include Vestal Point Capital, LP (US$99.9M), TCG Crossover Management, LLC (US$74.3M), Frazier Life Sciences Management, L.P. (US$62.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding DYN

All DYN fund holders →

FAQ

How long has Novo Holdings A/S held DYN?

Novo Holdings A/S has disclosed DYN holdings in 2 of the last 2 reported quarters, going back to Q2 2026.

What is Novo Holdings A/S's current position in DYN?

As of Q3 2026, Novo Holdings A/S holds 1.38M shares of DYN (DYNE THERAPEUTICS INC), valued at $22.17M, representing 1.49% of its reported portfolio and ranking #20.

Has Novo Holdings A/S been buying or selling DYN?

In the latest 13F filing (Q3 2026), Novo Holdings A/S increased its position in DYN. The position peaked in Q3 2026 at 1.38M shares.

Which other funds hold DYN?

Other major institutional holders of DYN include Vestal Point Capital, LP, TCG Crossover Management, LLC, Frazier Life Sciences Management, L.P., among 34 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.